Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
3.69B
Market cap3.69B
Price-Earnings ratio
41.65
Price-Earnings ratio41.65
Dividend yield
Dividend yield
Average volume
1.35M
Average volume1.35M
High today
$36.35
High today$36.35
Low today
$34.48
Low today$34.48
Open price
$35.50
Open price$35.50
Volume
3.20M
Volume3.20M
52 Week high
$117.33
52 Week high$117.33
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $35.01. The company's market cap stands at 3.69B, with a P/E ratio of 41.65.

On 2026-03-21, Corcept Therapeutics(CORT) stock traded between a low of $34.48 and a high of $36.35. Shares are currently priced at $35.01, which is +1.5% above the low and -3.7% below the high.

The Corcept Therapeutics(CORT)'s current trading volume is 3.2M, compared to an average daily volume of 1.35M.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.

In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.

CORT News

TipRanks 1d
Top Corcept Therapeutics Insider Makes Bold Multi-Million Dollar Move

New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on March 19, 2026. Director Leonard G. Baker has significantly increased his stake in C...

TipRanks 1d
Corcept Therapeutics director buys $3.3M in common stock

In a regulatory filing, Corcept Therapeutics (CORT) disclosed that its director Leonard Baker bought 100K shares of common stock on March 17th in a total transa...

Simply Wall St 6d
Corcept Therapeutics Is Down 5.1% After FDA Relacorilant Rejection And Investor Lawsuits - What's Changed

In late 2025, Corcept Therapeutics received a Complete Response Letter from the FDA rejecting its New Drug Application for relacorilant on the grounds of insuff...

Corcept Therapeutics Is Down 5.1% After FDA Relacorilant Rejection And Investor Lawsuits - What's Changed

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.